Lack of short-term modulation of in vitro placental progesterone secretion in sheep

Estrogen in the fetus

Estradiol and other estrogens are important modulators of fetal and maternal physiology in pregnancy. Much is known about the biosynthesis of estrogens in fetus and mother, and much is known about the role that estrogen plays in labor and delivery. However, much less is known about the regulation of estrogen biosynthesis throughout the latter half of gestation, and the role that estrogen plays in homeostatic and neuroendocrine control in the fetus. This review focuses on the biosynthesis and actions of estrogen in the fetal circulation, the role that it plays in the development of the fetus in the latter half of gestation, and the role that is played by the estrogen milieu in the control of the timing of birth. Estrogen circulates in fetal blood in both unconjugated and conjugated molecular forms, with the conjugated steroids far more abundant than the unconjugated steroids. This review therefore also addresses the biological significance of the variety of molecular forms of estrogen circulating in fetal and maternal blood.

Effects of prostaglandin F2 alpha (PGF2 alpha) on secretion of pregnancy specific protein B (PSPB) and placentome weights in intact or ovariectomized 90 to 100 day pregnant ewes

Vehicle or 8 or 16 mg PGF2 alpha/58 kg/body weight (BW) was given intramuscularly to intact or ovariectomized 90 to 100 day pregnant ewes in two separate experiments. Treatment with 8 mg PGF2 alpha in intact 90 to 100 day pregnant ewes increased (P < or = 0.05) placentome weights, but not in ovariectomized 90 to 100 day pregnant ewes (P > or = 0.05). Concentrations of PSPB in uterine venous plasma of control 90 to 100 day intact pregnant ewes over the 72 hour sampling period averaged 52 +/- 5 ng/ml. Profiles of PSPB in uterine plasma in the 16 mg PGF2 alpha/58 kg/BW-treated ewes differed (P < or = 0.05) from control or 8 mg PGF2 alpha-treated 90 to 100 day intact pregnant ewes. Pregnancy specific protein B was increased (P < or = 0.05) at 64 hr in intact 90 to 100 day pregnant ewes by treatment with 8 mg PGF2 alpha/58 kg/BW. There was a quadratic increase (P < or = 0.09) in PSPB in uterine venous plasma of all three treatment groups of intact 90 to 100 day pregnant ewes. Concentrations of PSPB in uterine venous plasma of control 90 to 100 day ovariectomized pregnant ewes over the 72 hr treatment period averaged 90 +/- 5 ng/ml. Profiles of PSPB did not differ among the vehicle, 8 mg PGF2 alpha or 16 mg PGF2 alpha-treated ovariectomized 90 to 100 day pregnant ewes. There was a quadratic increase (P < or = 0.10) in PSPB in uterine venous plasma of ovariectomized 90 to 100 day pregnant ewes treated with 8 or 16 mg PGF2 alpha/58 kg/BW. It is suggested that PSPB may have a role in regulating placental steroidogenesis.

Effect of prostaglandin F2 alpha on uterine or ovarian secretion of prostaglandins E and F2 alpha in vivo in 90-100 day hysterectomized, intact or ovariectomized pregnant ewes

Vehicle or 8 or 16 mg of PGF2 alpha per 58 kg body weight was given intramuscularly to intact, hysterectomized or ovariectomized 90-100 day pregnant ewes in three separate experiments. Both doses of PGF2 alpha increased PGF2 alpha in ovarian venous plasma compared with controls at 72 hr post treatment in intact (P < or = 0.05) but did not in hysterectomized (P > or = 0.05) 90-100 day pregnant ewes. Concentrations of PGE in ovarian venous blood of intact ewes did not differ (P > or = 0.05) between treatment groups and were equivalent to concentrations of PGE determined in uterine venous plasma. PGE was decreased in ovarian venous plasma by PGF2 alpha in hysterectomized ewes (P < or = 0.07). PGE in uterine venous plasma averaged 6 ng/ml over the 72-hr treatment period in intact and ovariectomized 90-100 day pregnant ewes and was 12 fold greater (P < or = 0.05) than PGF2 alpha which averaged 500 pg/ml in uterine venous plasma. Both PGF2 alpha and PGE increased (P < or = 0.05) by 64 hr in uterine venous plasma of the 8 mg PGF2 alpha-treated intact pregnant ewes. A significant quadratic increase (P < or = 0.05) was observed for PGF2 alpha and PGE in the vehicle and both PGF2 alpha treatment groups of intact ewes at the end of the 72-hr sampling period. It is concluded that the uterus and ovaries secrete significant quantities of PGF but little PGF2 alpha during midgestation. In addition, PGF2 alpha increased uterine secretion of PGE in vivo. PGE may be a placental stimulator of ovine placental secretion of progesterone or PGE may protect placental steroidogenesis from actions of PGF2 alpha.

20-alpha-Hydroxysteroid dehydrogenase from pseudopregnant rat ovary: obtention and characterization of a monoclonal antibody against the enzyme activity

The enzyme 20-alpha-hydroxysteroid dehydrogenase (20-alpha-HSD) was purified from pseudopregnant rat ovaries and used as antigen for the development of a monoclonal antibody by the hybridoma technique. Spleen cells of BALB/c mice immunized with purified 20-alpha-HSD were fused with SP2/0 mouse myeloma cells. Among the colonies of hybrid cells, one (designated mAb-HSD 11) was found to be secreting antibodies (IgM) able to inhibit 20-alpha-HSD activity. The antibody-secreting hybridome was amplified by ascitic fluid production and the monoclonal antibody purified by Bakerbond ABx procedure. Purified mAb-HSD 11 was able to inhibit 20-alpha-HSD activity in a dose-dependent manner. Studies of Michaelis constants of 20-alpha-HSD indicate that this monoclonal antibody increases the Km for 20-alpha-dihydroprogesterone and decreases the Vmax.

Evidence for modulation of progesterone secretion by calcium and protein kinase C activators in ovine chorionic cells

The hypothesis that calcium-dependent mechanisms may be involved in regulating ovine placental steroidogenesis was investigated using chorionic cells isolated by enzymatic digestion. Treatment of the cells with the calmodulin antagonist trifluoperazine (TFP) or pimozide caused a dose-related inhibition of progesterone (P4) production by 80 percent (P less than 0.001) at 40 microM TFP and 56 per cent (P less than 0.001) at 10 microM pimozide. Moreover, the conversion of 25 hydroxycholesterol (25 OH Chol.) to P4 was impaired in the presence of these compounds. These experiments suggest the involvement of a calcium-calmodulin system in the regulation of ovine placental P4 synthesis. Interestingly, calcium ionophore A23187 caused a gradual decline in P4 secretion and completely blocked it at 1 microM (P less than 0.001) and remains absent even in the presence of 25 OH Chol. In contrast, EGTA increased P4 secretion (P less than 0.01). Further, in the presence of 3 mM EGTA the inhibitory effect of 1 microM A23187 was fully reversed. Taken together these results suggest that extracellular calcium could play a role of negative modulation of P4 secretion in these cells. The possible involvement of protein kinase C (PKC) was tested using tumor-promoting phorbol ester (PMA) or permeant diacylglycerols (OAG or DOG). These compounds were unable to modify basal P4 secretion but reduced 25 OH Chol stimulated secretion to basal level. The phorbol ester that was unable to activate PKC had no effect on the metabolism of 25 OH chol. Thus, PMA and diacylglycerol effects are probably mediated by PKC. These data support the hypothesis that PKC activation plays a role in the modulation of cholesterol side-chain cleavage activity in ovine chorionic cells. These results show that calcium-dependent processes are involved in both positive and negative control of P4 secretion by ovine placenta. Our results also suggest a role for calmodulin and PKC pathways in modulating this secretion.

Differential control of placental lactogen release and progesterone production by ovine placental tissue in vitro

The hypothesis that placental secretion of progesterone (P4) and ovine placental lactogen (oPL) are controlled through different mechanisms was tested. Placental tissue was obtained at days 133-138 of pregnancy, and explant incubations were established using 200 mg tissue per flask in 5 ml O2-saturated DMEM containing 24 mM HEPES and lacking phenol red (pH 7.4). Following a 30-min preincubation, and a 15-min control period, test substances were added and incubations continued, with periodic gassing, for 4 h at 37 degrees C in a shaking water bath. Dopamine (DA), norepinephrine (NE) and epinephrine significantly stimulated P4 production (P less than 0.05). The enhancement of placental P4 production was mimicked by the addition of 8-bromo-cyclic adenosine monophosphate and forskolin (P less than 0.05). The response to catecholamines was abolished by the addition of propranolol (P less than 0.05) but not by phentolamine (P greater than 0.05). Inclusion of a membrane-permeant substrate for P4 synthesis, 25-hydroxycholesterol, increased basal (P less than 0.05) but did not enhance agonist-induced P4 production (P greater than 0.05). High performance liquid chromatographic analysis of placental tissue demonstrated the presence of DA (80.8 +/- 7.07 pg/mg) and NE (48.8 +/- 5.77 pg/mg), as well as catecholamine metabolites. Addition of 1,2-dioctanoyl-sn-glycerol (DAG) or phorbol 12-myristate-13-acetate (PMA) enhanced oPL secretion (P less than 0.05) without affecting P4 production. The response to DAG and PMA, representing the release of considerably more oPL than can be detected by extracting the tissue, was not influenced by treatment with cycloheximide (P greater than 0.05) indicating that secretion of preformed oPL is regulated by the protein kinase C pathway. These results support the hypothesis that the secretion of oPL and the production of P4 are controlled by different mechanisms.